Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.
You may also be interested in...
Takeda Avoids REMS For Entyvio, But Must Continue PML Monitoring
FDA approves drug for ulcerative colitis and Crohn’s disease patients who have failed other therapies, but requires heightened adverse event reporting and post-marketing study.
Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
Merck Bets Big On Oncology In New R&D Strategy
The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.